|
Basic Characteristics of Mutations
|
|
Mutation Site
|
C87S |
|
Mutation Site Sentence
|
Analysis of a single amino acid substitution of Compound-B-resistant DENV2 revealed that mutation C87S in the non-structural protein 4A (NS4A) contributes to resistance to Compound-B. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
NS4A |
|
Standardized Encoding Gene
|
NS4A
|
|
Genotype/Subtype
|
DENV-2 |
|
Viral Reference
|
LC367234
|
|
Functional Impact and Mechanisms
|
|
Disease
|
Cell line
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
Compound-B |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
29758236
|
|
Title
|
Identification of Compound-B, a novel anti-dengue virus agent targeting the non-structural protein 4A
|
|
Author
|
Nobori H,Toba S,Yoshida R,Hall WW,Orba Y,Sawa H,Sato A
|
|
Journal
|
Antiviral research
|
|
Journal Info
|
2018 Jul;155:60-66
|
|
Abstract
|
Dengue virus (DENV) is the causative agent of dengue fever and dengue hemorrhagic fever/dengue shock syndrome. At present, no antiviral drugs are available for treatment DENV infections. In this study, a screening system based on a DENV-infected cell-based assay identified a novel anti-DENV agent with a benzimidazole skeleton, named Compound-B, which demonstrated antiviral activity specific to four DENV serotypes (EC(50): 1.32-4.12 muM). Analysis of a single amino acid substitution of Compound-B-resistant DENV2 revealed that mutation C87S in the non-structural protein 4A (NS4A) contributes to resistance to Compound-B.
|
|
Sequence Data
|
-
|